News

Biomarkers May Help Develop Better and More Personalized Alzheimer’s Treatments, Study Suggests

The physical properties of proteins in the spinal fluid and blood of people with Alzheimer’s disease may constitute valuable biomarkers to help diagnose disease progression and predict patients’ outcomes, new research from The Ohio State University suggests. The biomarkers may help researchers develop better treatments in the future, especially for later stages of…

Pain Therapeutics’ PTI-125, Potential Treatment for Alzheimer’s, to Undergo Phase 1 Clinical Trial

Pain Therapeutics will soon launch a Phase 1 clinical trial to study the safety and efficacy of PTI-125 in treating Alzheimer’s disease. The announcement came after the U.S. Food and Drug Administration (FDA) accepted the company’s investigational new drug application for the therapy. It follows a recently awarded $1.7 million research grant by the…

Regenacy’s HDAC Blocker Improved Cognitive Function in Mice with Alzheimer’s, Study Shows

A compound that blocks the activity of so-called HDAC enzymes in the brain improved learning in mouse models of Alzheimer’s disease, according to data that Regenacy Pharmaceuticals presented at the recent 2017 Alzheimer’s Association International Conference (AAIC) July 16-20 in London. Regenacy’s RCY-1305 blocks the enzymes HDAC1 and HDAC2, which…